Type something and hit enter

 [PHARMANIAGA BHD:非特许业务的需求增加,这主要是由于持续的Covid-19大流行导致个人防护设备的销售增加]

2Q20 vs 2Q19:

YTD20 vs YTD19:




2Q20 vs 1Q20:


James Ng Stock Pick Performance:
Since Recommended Return:

a. FRONTKEN CORP BHD, recommended on 12 Aug 18, initial price was RM0.715, rose to RM3.72, dividend RM0.04, in 2 years 15 days, total return is 425.9%

b. TOP GLOVE CORP BHD, recommended on 1 July 18, initial price was RM12.14, rose to RM52.80 adjusted, dividend RM0.52, in 2 Years 1 month 26 days, total return is 339.2%

c. MI TECHNOVATION BERHAD, recommended on 2 Jun 19, initial price was RM1.67, rose to RM6.56 adjusted, dividend RM0.055, in 1 Year 2 months 25 days, total return is 296.1%

d. OPENSYS M BHD, recommended on 24 May 20, initial price was RM0.355, rose to RM0.985, dividend RM0.0025, in 3 months 3 days, total return is 178.2%

e. KKB ENGINEERING BHD, recommended on 1 Jul 18, initial price was RM0.795, rose to RM1.60, dividend RM0.04, in 2 Years 1 month 26 days, total return is 106.3%

f. KAREX BHD, recommended on 20 Oct 19, initial price was RM0.445, rose to RM0.885, dividend RM0.015, in 10 months 7 days, total return is 102.2%

g. PERAK TRANSIT BHD, recommended on 19 Jul 20, initial price was RM0.18, rose to RM0.27, in 1 month 8 days, total return is 50%

h. MGB BHD, recommended on 1 March 20, initial price was RM0.565, rose to RM0.82, in 5 months 26 days , total return is 45.1%

i. PROLEXUS BHD, recommended on 25 Aug 19, initial price was RM0.455, rose to RM0.655, dividend RM0.003, in 1 Year 2 days, total return is 44.6%

j. DESTINI BHD, recommended on 24 Sep 19, initial price was RM0.20, rose to RM0.28, in 11 months 3 days, total return is 40%

我希望将我的策略分享给读者,希望他们在阅读后能够表现出色。我正在使用基本面分析Fundamental Analysis:



我为想从马来西亚股票市场赚钱的读者提供STOCK PICK服务。想订阅我的邮件以从股票市场获取良好回报的人,可以通过jamesngshare@gmail.com 或我的FB页面与我联系。

Whatsapp : 011 - 15852043

请订阅James的股票投资James Share Investing的Youtube频道:https://www.youtube.com/c/JamesShareInvesting

Facebook Group: https://www.facebook.com/groups/jamesinvesting

这个是我的TELEGRAM Group链接: https://t.me/joinchat/LhwHNhdU1fDgxrSafTrTiw

请大家来Follow James的Instagram,获取最新的资讯:jamesnginvest


James Ng
[PHARMANIAGA BHD: increased demand in the non-concession business, primarily as a result of higher sales of personal protective equipment due to the ongoing Covid-19 pandemic]

2Q20 vs 2Q19:
For the second quarter ended 30 June 2020, the Group delivered an improved revenue of RM646 million, up by 7.3% compared with RM602 million in the previous year’s corresponding quarter. This was driven by increased demand in the non-concession business, primarily as a result of higher sales of personal protective equipment due to the ongoing Covid-19 pandemic. As a result, the Group turned in a profit before zakat and taxation (PBT) of RM14 million, reflecting a growth of 14.8% compared with last year’s corresponding quarter. Accordingly, profit after tax (PAT) for the quarter under review grew by 3.7% to RM10 million, compared with RM9 million in the same quarter last year.

YTD20 vs YTD19:
For the first six months of the financial year under review, the Group delivered a higher revenue of RM1.5 billion compared with RM1.4 billion in the same period last year. This was achieved on the back of stronger contributions from the non-concession business, mainly due to higher sales of personal protective equipment in response to the Covid-19 outbreak. This saw the Group's PBT increase by 5.8% to RM45 million. As a result, the Group recorded a higher PAT of RM32 million compared with RM29 million in the same period last year.

The Logistics and Distribution Division turned in a higher PBT of RM37 million for the first six months, up by 96% compared with RM19 million in the same period last year. This was driven by improved contributions from the non-concession business.

The Manufacturing Division posted a PBT of RM13 million on the back of a revenue of RM137 million, in line with order trends from Government hospitals. The outlook remains positive for the Division, with new product launches in the pipeline. In addition, further expansion into overseas markets, as well as increased capacity utilisation via its contract manufacturing business will be pursued by the Group.

The Indonesia Division recorded a deficit of RM2 million.

2Q20 vs 1Q20:
PAT for the quarter under review stood at RM10 million, compared with RM22 million in the immediate preceding quarter.

Moving forward, the Group remains committed to strengthen operations across all its Divisions and endeavoring in new ventures in line with the current healthcare industry. Along with serving the healthcare requirements of the Rakyat, this will enable the Group to continue delivering better results.

Taking a longer-term perspective, the Group is focused on enhancing prospects by improving manufacturing and operational efficiencies, as well as progressing in its research and development efforts. This will allow Pharmaniaga to tap on new opportunities, both in Malaysia and overseas markets, to ensure the sustainable growth of the Group in the years ahead.
I wish to share my strategy to readers, hope that they can perform well after reading this. I am using Fundamental Analysis:

the forecasted growth of a company must over 14% per year

I wish to convince readers to learn FA in order to make money from stock market.

I am providing STOCK PICK SERVICE for readers who want to make money from Malaysian stock market. Those who want to subscribe to my mailing list to achieve a good return from stock market, you can contact me at jamesngshare@gmail.com or PM me in my FB page.

This sharing is purely a discussion and analysis of the sector, buying or selling at your own risk. Please Like and Share this post. Final decision is always yours, thank you.

James Ng


Click to comment
Back to Top
Back to Top